Your browser doesn't support javascript.
loading
SARS-CoV-2 correlates of protection from infection against variants of concern.
Sun, Kaiyuan; Bhiman, Jinal N; Tempia, Stefano; Kleynhans, Jackie; Madzorera, Vimbai Sharon; Mkhize, Qiniso; Kaldine, Haajira; McMorrow, Meredith L; Wolter, Nicole; Moyes, Jocelyn; Carrim, Maimuna; Martinson, Neil A; Kahn, Kathleen; Lebina, Limakatso; du Toit, Jacques D; Mkhencele, Thulisa; von Gottberg, Anne; Viboud, Cécile; Moore, Penny L; Cohen, Cheryl.
Affiliation
  • Sun K; Division of International Epidemiology and Population Studies, Fogarty International Center, National Institutes of Health, Bethesda, MD, USA. kaiyuan.sun@nih.gov.
  • Bhiman JN; SAMRC Antibody Immunity Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
  • Tempia S; Centre for HIV and STIs, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
  • Kleynhans J; Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
  • Madzorera VS; School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Mkhize Q; Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Kaldine H; Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
  • McMorrow ML; School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Wolter N; SAMRC Antibody Immunity Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
  • Moyes J; Centre for HIV and STIs, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
  • Carrim M; SAMRC Antibody Immunity Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
  • Martinson NA; Centre for HIV and STIs, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
  • Kahn K; SAMRC Antibody Immunity Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
  • Lebina L; Centre for HIV and STIs, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
  • du Toit JD; Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Mkhencele T; COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • von Gottberg A; Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
  • Viboud C; School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Moore PL; Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
  • Cohen C; School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Nat Med ; 2024 Jul 26.
Article in En | MEDLINE | ID: mdl-39060660
ABSTRACT
Serum neutralizing antibodies (nAbs) induced by vaccination have been linked to protection against symptomatic and severe coronavirus disease 2019. However, much less is known about the efficacy of nAbs in preventing the acquisition of infection, especially in the context of natural immunity and against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immune-escape variants. Here we conducted mediation analysis to assess serum nAbs induced by prior SARS-CoV-2 infections as potential correlates of protection against Delta and Omicron infections, in rural and urban household cohorts in South Africa. We find that, in the Delta wave, D614G nAbs mediate 37% (95% confidence interval 34-40%) of the total protection against infection conferred by prior exposure to SARS-CoV-2, and that protection decreases with waning immunity. In contrast, Omicron BA.1 nAbs mediate 11% (95% confidence interval 9-12%) of the total protection against Omicron BA.1 or BA.2 infections, due to Omicron's neutralization escape. These findings underscore that correlates of protection mediated through nAbs are variant specific, and that boosting of nAbs against circulating variants might restore or confer immune protection lost due to nAb waning and/or immune escape. However, the majority of immune protection against SARS-CoV-2 conferred by natural infection cannot be fully explained by serum nAbs alone. Measuring these and other immune markers including T cell responses, both in the serum and in other compartments such as the nasal mucosa, may be required to comprehensively understand and predict immune protection against SARS-CoV-2.

Full text: 1 Database: MEDLINE Language: En Journal: Nat Med Journal subject: BIOLOGIA MOLECULAR / MEDICINA Year: 2024 Type: Article Affiliation country: United States

Full text: 1 Database: MEDLINE Language: En Journal: Nat Med Journal subject: BIOLOGIA MOLECULAR / MEDICINA Year: 2024 Type: Article Affiliation country: United States